Cargando…

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination

SIMPLE SUMMARY: Leukemic cells evade chemotherapy due to interactions within the bone marrow microenvironment. We have tested the effect of epigenetic therapy on pediatric AML cells in multicell coculture and in murine models. Epigenetic drug combination followed by chemotherapy was effective in ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehner, Kara M., Gopalakrishnapillai, Anilkumar, Kolb, Edward Anders, Barwe, Sonali P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296268/ https://www.ncbi.nlm.nih.gov/pubmed/37370721 http://dx.doi.org/10.3390/cancers15123112

Ejemplares similares

Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies
por: Quagliano, Anthony, et al.
Publicado: (2023)

Metformin suppresses pediatric acute myeloid leukemia cell viability and clonogenicity
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2014)

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology
por: Barwe, Sonali P., et al.
Publicado: (2020)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
por: Quagliano, Anthony, et al.
Publicado: (2020)

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
por: Barwe, Sonali P., et al.
Publicado: (2022)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies
por: Sidhu, Ishnoor, et al.
Publicado: (2021)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2015)

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
por: Barwe, Sonali P., et al.
Publicado: (2022)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
por: Garcia-Manero, G, et al.
Publicado: (2017)

Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia
por: Tarighat, Somayeh S., et al.
Publicado: (2021)

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2016)

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring
por: Crowgey, Erin L., et al.
Publicado: (2020)

Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
por: Cheung, Laurence C., et al.
Publicado: (2022)

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
por: Tan, P, et al.
Publicado: (2014)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome
por: Bloh, Kevin M., et al.
Publicado: (2017)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
por: Menghrajani, Kamal, et al.
Publicado: (2022)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes
por: Alonso, Salvador, et al.
Publicado: (2015)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

PB1760: AZACITIDINE AS TREATMENT OF KMT2A INFANT ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER EXPERIENCE
por: Giagnuolo, G., et al.
Publicado: (2022)

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Dabrafenib–Panobinostat Salt: Improving the Dissolution Rate and Inhibition of BRAF Melanoma Cells
por: Rai, Sunil K., et al.
Publicado: (2023)

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples
por: Barwe, Sonali P., et al.
Publicado: (2020)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
por: Almeida, António, et al.
Publicado: (2016)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

The Diversity of Chemoprotective Glucosinolates in Moringaceae (Moringa spp.)
por: Fahey, Jed W., et al.
Publicado: (2018)

Chemoprotective and chemosensitizing effects of apigenin on cancer therapy
por: Nozhat, Zahra, et al.
Publicado: (2021)

Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions
por: Massoth, Lucas R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vodohhn7n2b6ic2al00stpp8pe